MRK 125.44 (-2.09%)
US58933Y1055Drug ManufacturersDrug Manufacturers - General

Last update on 2024-03-05

Merck (MRK) Explained

An Overview of MRK: Its Business Strategy, Core Products, Major Competitors, and Essential Insights into its Role in the Drug Manufacturers - General Industry

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firms immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the companys sales are generated in the United States.

Article Cover Image

Current Business Strategy

Merck & Co., Inc., known as Merck in the United States and Canada and MSD outside, focuses on innovating new therapies and vaccines to address significant unmet medical needs. Their strategy encompasses a broad approach in areas like oncology, vaccines, hospital acute care, and animal health, with a significant emphasis on research and development (R&D) to bolster their pipeline. Furthermore, strategic collaborations, acquisitions, and licensing agreements play a pivotal role in their efforts to expand their product offerings and enter new markets.

Most known Products

Here is the list of the 5 most well-known products of Merck (MRK):

  • Keytruda: An immunotherapy drug used for the treatment of various types of cancer by enhancing the body’s immune system to fight cancer cells.
  • Gardasil: A vaccine designed to prevent human papillomavirus (HPV) infections, which can lead to cervical cancer, other HPV-associated cancers, and genital warts.
  • Januvia: A medication used to lower blood sugar levels in adults with type 2 diabetes mellitus, working by increasing levels of certain natural substances that lower blood sugar.
  • Bravecto: An animal health product offering up to 12 weeks of protection against fleas and ticks in dogs and cats, supporting a critical segment of Merck's product lineup.
  • Pneumovax 23: A pneumococcal vaccine that helps protect against infections caused by pneumococcus bacteria, such as meningitis and bloodstream infections.


Here is the list of the main 5 competitors of Merck (MRK):

  • PFE: Pfizer Inc. is a competitor primarily due to its vast portfolio in vaccines, oncology, and internal medicine, competing directly with Merck’s products such as Gardasil and Keytruda.
  • JNJ: Johnson & Johnson operates across a broad spectrum of the healthcare industry, including pharmaceuticals where its products in oncology and immunology rival those of Merck.
  • GSK: GlaxoSmithKline plc competes in various areas including vaccines and pharmaceuticals, notably in the respiratory and HIV segments, positioning it as a key competitor against Merck’s vaccine and therapeutic offerings.
  • ABBV: AbbVie Inc., with its strong portfolio in immunology, oncology, and virology, including blockbuster drugs, competes in key therapeutic areas with Merck.
  • BMY: Bristol-Myers Squibb Company has a significant presence in oncology and cardiovascular diseases, going head-to-head with Merck, especially in the rapidly growing area of immuno-oncology.

Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the website or other media used.